1995
Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A
Vlahov D, Khabbaz R, Cohn S, Galai N, Taylor E, Kaplan J. Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 9: 89-96. PMID: 7712239, DOI: 10.1097/00042560-199505010-00013.Peer-Reviewed Original ResearchConceptsRisk factorsDrug usersEnzyme immunoassayWestern blotHuman T-lymphotropic virusNeedle-sharing practicesRisk factor analysisT-lymphotropic virusMedian lag timeCase-control designALIVE studyRecent serumSeronegative IDUsStudy entryBaseline historyIncidence rateSeroconversionPositive casesSex partnersIDUsHTLVCalendar timeMonthsIncidenceBaseline
1994
Changes in HIV Risk Behaviors among Counseled Injecting Drug Users
Mandell W, Vlahov D, Latkin C, Carran D, Oziemkowska M, Reedt L. Changes in HIV Risk Behaviors among Counseled Injecting Drug Users. Journal Of Drug Issues 1994, 24: 555-567. DOI: 10.1177/002204269402400314.Peer-Reviewed Original ResearchHIV risk behaviorsRisk behaviorsShort-term educational interventionHIV-seronegative IDUsEducational interventionInjecting Drug UsersIntensive educational interventionSeronegative IDUsHIV infectionSignificant additional benefitSix monthsDrug usersDrug useEducational sessionsIntensive interventionReduction of activityOne hourInterventionIDUsCommunity sampleFifteen minutesInjection equipmentMonthsRisky behaviorsAdditional benefit